Brief: Celldex Presents Phase 2 Study In Chronic Spontaneous Urticaria At Eaaci Congress 2025
12/06/2025 23:03
June 12 (Reuters) - Celldex Therapeutics Inc CLDX.O: CELLDEX PRESENTS UNPRECEDENTED 76 WEEK RESULTS FROM BARZOLVOLIMAB PHASE 2 STUDY IN CHRONIC SPONTANEOUS URTICARIA AT EAACI CONGRESS 2025 Source text: ID:nGNXX47cZ Further company coverage: CLDX.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Celldex Therapeutics
See all newsUS RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Celldex shares slip as safety concerns cloud skin drug trial win (updated)
Celldex falls after two probable anaphylaxis cases in trials
Celldex's skin disease drug meets goals in two late-stage trials